Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US0042251084
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG000BHG9K0
ACAD
ACADIA Pharmaceuticals Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
ACADIA Pharmaceuticals Inc
ISIN
US0042251084
TICKER
ACAD
MIC
XNAS
REUTERS
ACAD.OQ
BLOOMBERG
ACAD US
Mon, 24.08.2026       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.08.2026       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2026. “Acadia delivered an outstanding second quarter, highlighted by strong commercial execution across both DAYBUE and NUPLAZID, resulting in total revenue growth of 17% year-over-year on an adjusted basis,” said Catherine Ow...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.07.2026       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 1:30 p.m. Eastern Time. Live webcasts will be accessible on the company’s website, acadia.com, under the investors section and an archived recording will be ava...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 20.07.2026       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to remlifanserin, an investigational, highly selective, 5-HT2A receptor inverse agonist, for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). Fast Track d...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.07.2026       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on August 4, 2026, at 4:30 p.m. Eastern Time. The conference call will be available o...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.07.2026       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Carl Segerstrom as Chief People Officer, effective July 6. Carl will lead the company’s global people and culture strategy, supporting its next phase of growth as a leading neurological and rare disease company focused on advancing therapies for patients with significant...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Fri, 26.06.2026       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral sy...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 06.05.2026       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2026. “Acadia delivered a solid first quarter of 2026 with total revenues of $268 million, driven by a strong start from DAYBUE, which generated sales of $101 million,” said Catherine Owen Adams, Chief Executive Officer. “We ar...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.04.2026       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the planned retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development. Dr. Thompson has decided to retire for personal reasons and informed Acadia of her plans. She will continue in her role as Head of Research and Development until a successor is appointed. After her...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 28.04.2026       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: BofA Securities 2026 Health Care Conference Fireside Chat: Tuesday, May 12, 2026 at 4:20 p.m. Pacific Time in Las Vegas, NV 2026 RBC Capital Markets Global Healthcare Conference Fireside Chat: Tuesday, May 19, 2026 at 9:00...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Fri, 17.04.2026       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present multiple original data presentations spanning its portfolio at the 2026 American Academy of Neurology (AAN) Annual Meeting, taking place April 18–22, 2026 in Chicago, IL. The Company will present real-world data from a sub-group analysis of the ongoing, Phase 4, pros...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.04.2026       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter 2026 financial results on Wednesday, May 6, 2026, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on May 6, 2026, at 4:30 p.m. Eastern Time. The conference call will be available on Aca...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced DAYBUE® STIX (trofinetide) for oral solution, a dye- and preservative-free powder formulation of trofinetide, is now broadly available in the United States for the treatment of Rett syndrome in adults and pediatric patients two years of age and older. The new formulation, approved by the U...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 12.03.2026       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Tuesday, March 17, 2026 at 8:00 a.m. Eastern Time. A live webcast of Acadia’s fireside chat will be accessible on the company’s website, acadia.com, under the investors section and an archived recording w...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 03.03.2026       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Jonathan M. Poole to its Board of Directors, effective March 3, 2026. Mr. Poole will serve on the Company’s Audit Committee and brings deep biopharmaceutical finance leadership experience in supporting global growth and innovation across multiple therapeutic areas and mo...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 02.03.2026       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) informed the company it has formally adopted a negative opinion regarding the Marketing Authorization Application for trofinetide for the treatment of Rett syndrome in patients two years o...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 25.02.2026       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the fourth quarter and full year ended December 31, 2025. “Acadia closed 2025 with another strong quarter, capping a milestone year in which we surpassed $1 billion in annual revenue for the first time,” said Catherine Owen Adams, Chief Executive Officer. “NUPL...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 23.02.2026       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences: TD Cowen's 46th Annual Health Care Conference Fireside Chat: Monday, March 2, 2026 at 11:10 a.m. Eastern Time in Boston, MA The Citizens Life Sciences Conference Fireside Chat: Wednesday, March 11, 2026 at 1:05 p.m. Easte...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 04.02.2026       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on February 25, 2026, at 4:30 p.m. Eastern Time. The conference ca...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 02.02.2026       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Company was informed by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of a negative trend vote on its Marketing Authorization Application (MAA) for trofinetide for the treatment of Rett syndrome, following its recent CHMP oral exp...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 13.01.2026       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced multiple business updates and progress on the Company's neurological and rare disease drug candidates, which will be discussed today during a presentation by Catherine Owen Adams, Chief Executive Officer, at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. “2026 ma...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 18.12.2025       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Catherine Owen Adams, Chief Executive Officer will represent the company in a session scheduled on Tuesday, January 13, 2026, at 9:45 a.m. Pacific Time / 12:45 p.m. Eastern Time. A live webcast...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Fri, 12.12.2025       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has approved DAYBUE® STIX (trofinetide) for oral solution, a dye- and preservative-free powder formulation of trofinetide for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. The new formulation is e...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 20.11.2025       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Citi’s 2025 Global Healthcare Conference on Tuesday, December 2, 2025 at 9:45 a.m. Eastern Time. A live webcast of Acadia’s fireside chat will be accessible on the company’s website, acadia.com, under the investors section and an archived re...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 05.11.2025       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2025. “Acadia delivered another strong quarter, generating total revenue of $278.6 million,” said Catherine Owen Adams, Chief Executive Officer. “NUPLAZID achieved record sales of $177.5 million representing a significant inf...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 28.10.2025       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: UBS Global Healthcare Conference Fireside Chat: Monday, November 10, 2025 at 2:00 p.m. Eastern Time in Palm Beach Gardens, FL Jefferies Global Healthcare Conference in London Presentation: Tuesday, November 18, 2025 at 8:30...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 28.10.2025       ACADIA Pharmaceuticals
US0042251084

NEW YORK, Oct. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.10.2025       ACADIA Pharmaceuticals
US0042251084

NEW YORK, Oct. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.10.2025       ACADIA Pharmaceuticals
US0042251084

Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) breached their fiduciary duties to shareholders. If you currently own Acadia stock and acquired shares on or before September 9, 2019, you may be able to seek corporate governance reforms, the retur...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.10.2025       ACADIA Pharmaceuticals
US0042251084

Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, Oct. 21, 2025 /CNW/ -- Equ...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.10.2025       ACADIA Pharmaceuticals
US0042251084

Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, Oct. 21, 2025 /PRNewswire/...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.10.2025       ACADIA Pharmaceuticals
US0042251084

Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, Oct. 21, 2025 /PRNewswire/...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Sat, 18.10.2025       ACADIA Pharmaceuticals
US0042251084

NEW YORK, Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.10.2025       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2025 financial results on Wednesday, November 5, 2025, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on November 5, 2025, at 4:30 p.m. Eastern Time. The conference call will be availa...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 13.10.2025       ACADIA Pharmaceuticals
US0042251084

NEW YORK, Oct. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 08.10.2025       ACADIA Pharmaceuticals
US0042251084

NEW YORK, Oct. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.10.2025       ACADIA Pharmaceuticals
US0042251084

NEW YORK, Oct. 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 02.10.2025       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced one late-breaker oral platform presentation and two poster presentations to be presented at the International Congress of Parkinson’s Disease and Movement Disorders® being held October 5-9, 2025, in Honolulu, Hawaii. The presentations highlight updates from the company’s robust pipeline...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 24.09.2025       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin (ACP-101) in patients with hyperphagia in Prader-Willi syndrome (PWS). Intranasal carbetocin did not demonstrate a statistically significant improvement over placebo on the study...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 24.09.2025       ACADIA Pharmaceuticals
US0042251084

Instrument ID [8108] (DR6 - US0042251084) suspended...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Fri, 12.09.2025       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the journal Developmental Medicine and Child Neurology published interim results from the caregiver-reported observational online, open-label, ongoing LOTUS study evaluating effectiveness and tolerability outcomes in patients with Rett syndrome who are prescribed DAYBUE® (trofinetide)...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 08.09.2025       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on September 4, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 161,676 shares of common stock and 49,363 restricted stock units (“RSUs”) to eighteen new employees under A...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 26.08.2025       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences: Morgan Stanley 23rd Annual Global Healthcare Conference Fireside Chat: Monday, September 8, 2025 at 10:45 a.m. Eastern Time in New York, NY H.C. Wainwright 27th Annual Global Investment Conference Fireside Chat: Tuesday,...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 25.08.2025       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Konstantina (“Tina”) Katcheves as Senior Vice President, Chief Business and Strategy Officer. In this role, Tina will lead Acadia’s business development and corporate strategy and serve as a member of the Company’s Executive Leadership Team, reporting to Catherine Owen A...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 23.07.2025       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter financial results on Wednesday, August 6, 2025, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on August 6, 2025, at 4:30 p.m. Eastern Time. The webcast will be available on Acadia’s...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 03.07.2025       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on July 2, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 35,607 shares of common stock and 29,571 restricted stock units (“RSUs”) to seventeen new employees under Acadia...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 25.06.2025       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) will host its inaugural 2025 R&D Day today to highlight its key pipeline programs and their potential to drive long-term growth. Across nine disclosed programs, the Company anticipates initiating seven Phase 2 or Phase 3 studies during 2025-2026. Acadia further anticipates reporting five Phase 2 or...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 17.06.2025       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on June 6, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 187,664 shares of common stock and 89,582 restricted stock units (“RSUs”) to forty one new employees under Acadi...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 09.06.2025       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed a decision issued by the U.S. District Court for the District of Delaware in December 2023 confirming validity of the NUPLAZID® (pimavanserin) '740 composition of matter patent. The affirmance came in Acadia’s litigation again...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 05.06.2025       ACADIA Pharmaceuticals
US0042251084

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced it will host a R&D day in New York City to discuss its neurological and rare diseases pipeline on Wednesday, June 25, 2025 at 8:30 AM ET. The event will feature members of Acadia’s management team and R&D organization, key opinion leaders (KOL) and members of the caregiver commun...
Read more
ACADIA Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink